N※N

Supplement Industry and FDA Clash Over Ingredient Approvals

  //food-wine.news-articles.net/content/2026/03/28 .. try-and-fda-clash-over-ingredient-approvals.html
  Published in Food and Wine on Saturday, March 28th 2026 at 12:04 GMT by ABC7
      Locale: UNITED STATES

SAN FRANCISCO, March 28th, 2026 -- The dietary supplement industry is locked in a tense standoff with the Food and Drug Administration (FDA) over the regulation of novel ingredients, most notably peptides and other recently developed compounds. Industry leaders are voicing increasing frustration with the current pre-market approval process, arguing it's crippling innovation and hindering consumer access to potentially beneficial health and wellness products. The debate, which began in earnest following a landmark 2018 Supreme Court decision, shows no signs of immediate resolution.

For decades, the dietary supplement industry operated under a relatively lenient framework. Ingredients introduced before 1994 were generally considered grandfathered in, allowing companies to bring new formulations to market without undergoing the rigorous pre-approval process required for pharmaceuticals. However, the Supreme Court, in a ruling that significantly altered the landscape, determined this historical use provision was insufficient to ensure product safety.

Now, any ingredient considered "new" - meaning not marketed in the U.S. before 1994 - must navigate the same demanding pre-market approval process as conventional drugs. This involves submitting extensive data on safety, efficacy, and manufacturing quality to the FDA for review. While designed to protect consumers, supplement manufacturers contend the process is excessively burdensome, slow, and financially prohibitive, particularly for smaller companies.

"We have incredible ingredients, ranging from specific peptide chains showing promise in athletic recovery to novel plant extracts with potential cognitive benefits, that can positively impact health and wellness, but we simply can't get them to consumers under the current system," explained Daniel Fabricant, president of the Natural Products Association, in a recent interview. "The FDA's approach is stifling innovation and creating a bottleneck that's ultimately harming those who could benefit most."

Dr. Robert Kirsch, Director of the FDA's Division of Dietary Supplements, firmly defended the agency's position. "Our primary responsibility is to protect the American public, and that means ensuring that any substance intended for consumption is safe and effective. This isn't a matter we're willing to compromise on," he stated. He acknowledged the backlog of applications, currently exceeding 30 new ingredients, but emphasized the need for thorough evaluation. "We're trying to be as efficient as possible, but we won't rush a process that directly impacts public health."

The implications extend beyond the industry itself. Consumers are increasingly aware of, and seeking out, supplements for a wide range of health concerns, from boosting immunity to improving athletic performance. The regulatory hurdles mean potentially valuable products remain unavailable, creating frustration and a sense of lost opportunity. Shoppers interviewed outside a San Francisco health food store expressed mixed feelings. "I wish they would approve more things," one customer commented. "Sometimes you feel like you're missing out on products that could really help, especially with everything going on in the world." Another voiced concerns about safety, acknowledging the need for oversight but suggesting a tiered system where ingredients with a strong safety profile could be expedited.

Interestingly, even established supplements that enjoyed decades of pre-1994 use are technically subject to this new scrutiny. Products like creatine and glucosamine, staples in the supplement aisle, would theoretically require FDA approval if they were newly introduced today. This highlights the sweeping impact of the Supreme Court ruling and the challenges facing both regulators and industry stakeholders.

The core of the debate lies in differing philosophies regarding risk assessment. Supplement companies argue that ingredients with a demonstrated history of safe use in other countries should be granted a faster pathway to market, while the FDA maintains that US-specific data is crucial for ensuring safety and efficacy in the American population. Several proposed solutions, including a streamlined notification process for ingredients with well-documented safety profiles and increased funding for the FDA's Division of Dietary Supplements, are currently being discussed in Washington. The situation remains fluid, and a resolution that balances consumer protection with industry innovation is critical to ensure the continued growth and accessibility of the dietary supplement market.